Back to Stakeholders
Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchUniversities and Colleges with Dedicated Psychedelic Research Groups
Research, Drug Development & ManufacturingAcademic & Non-Profit Research
Research, Drug Development & Manufacturing

University of California, San Francisco

Also known as: University of California San Francisco, UC San Francisco, UCSF, UCSF Translational Psychedelic Research Program, UCSF TrPR, Psychedelics Division, Neuroscape, UCSF, University of California, San Francisco

United StatesUnited States
14 Trials1 Paper

University of California, San Francisco (UCSF) hosts major psychedelic research activity through the Translational Psychedelic Research Program (TrPR), Neuroscape Psychedelics Division, and psychiatry-led clinical research on psychedelic-assisted therapies.

Academic Research

1 papers

Published Papers

1

Trial Involvement

14

Distinct Focus Topics

0

Latest Publication

Mar 18, 2026

Quick Facts

Type
academic
HQ
United States
Website
Visit

Sponsored Trials

10
RecruitingI, II

RCT of Psilocybin-assisted CBT for Depression

Start Date
Compounds
Psilocybin, Placebo
Recruiting

Mapping Ibogaine Neural Dynamics in Opioid Use Disorder

Start Date
Compounds
Ibogaine
WithdrawnII

MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents

Start Date
Compounds
MDMA
RecruitingI

Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults

Start Date
Compounds
Psilocybin
RecruitingI

Safety Profile of Psilocybin for Cocaine Use Disorder

Start Date
Compounds
Psilocybin
CompletedI

Psilocybin-assisted CBT for Depression

Start Date
Compounds
Psilocybin
Active not recruitingI

Comparing the Effects of Psilocin and Psilocybin in Healthy Adults

Start Date
Compounds
Psilocybin
RecruitingI

Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain

Start Date
Compounds
Psilocybin
Active not recruitingII

Psilocybin Therapy for Depression in Bipolar II Disorder (BAP)

Start Date
Compounds
Psilocybin
CompletedI

Biomarkers of Fast Acting Therapies in Major Depression

Start Date
Compounds
Ketamine

Collaborated Trials

4
RecruitingI

Safety and Tolerability Trial of Psilocybin in Healthy Older Adults

Start Date
Compounds
Psilocybin
RecruitingI

Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability (PHATHOM)

Start Date
Compounds
Psilocybin
RecruitingII

Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC)

Start Date
Compounds
Psilocybin, Ketamine
CompletedII

Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder

Start Date
Compounds
Psilocybin

Research Papers

1
Paywallmeta

Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding Conditions A Systematic Review and Meta-Analysis

This meta-analysis (s=24) found that psychedelic-assisted therapy (s=8) was no more effective than open-label traditional antidepressants for treating major depression, and that, unlike traditional antidepressants (where blinding meaningfully influenced outcomes), PAT trials showed no difference between blinded and open-label conditions, confirming that PAT trials are effectively always unblinded.

Published
Journal
JAMA Psychiatry
Authors
Williams, Z. J., Barnett, H., Szigeti, B.